🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

IPI+NIVO after prior PD1/L1 in HCC? ➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4) ➡️ORR 22% (7/32) ➡️All responders to late line IPI+NIVO had NONRESPONSE to prior PD1/L1 ncbi.nlm.nih.gov/pmc/articles/P…

🔥TACE + durvalumab +/- bevacizumab in HCC #GI24 ✅ EMERALD-1, 616 pts 👉 ORR: 41 vs 43 vs 29% 👉 mPFS: 15 vs 10 vs 8.2 mo 👉 mOS: too early... 🧐Interesting data, no Durva mono benefit? Bev adds efficacy (again) … Practice changing? ESMO - Eur. Oncology ILCA EASLnews #livertwitter

Endoscopic variceal ligation vs propranolol for prevention of oesophageal variceal bleeding in HCC Gut Journal doi.org/10.1136/gutjnl… 🔎🇹🇼phs-II: HCC + medium/large varices 👉EVL is superior to PPL in preventing initial EVB 👉No differences in EVB + OS in BCLC C/D ‼️No treatment

Ipi/nivo in 1L #HCC is positive! (CheckMate-9DW study). Excited to see the full data soon... news.bms.com/news/corporate…

Important NCI funded ETCTN study. Even negative data is informative! Congratulations @VUMCHemOnc Dr. Cathy Eng #MedIQASCO24 #biliarytractcancer #ASCO24

The P3 #CheckMate9DW study (1L ipilimumab + nivolumab) is positive! Data are particularly compelling considering control arm (mostly lenva whereas others went up against sora only) and significant crossover to 2L IO from the control arm. #HCC #ASCO2024

Top 3 GI abstracts from #ASCO24: CheckMate 9DW - Nivo + Ipi vs TKI (sorafenib or lenvatinib) as 1L therapy of HCC. Nivo + Ipi: ⬆️mOS (23.7 vs 20.6 mos) ⬆️ORR (36% vs 13%) ⬆️mDoR (30.4 vs 12.9 mos) 🟰mPFS (9.1 vs 9.2 mos) Three 1L options. How to compare them?🧵👇 @oncoalert

Most impressive data from #CheckMate9DW (frontline nivo/ipi in #HCC) is the median duration of response: 30.4 months❗️Reaffirms something we've seen time and time again⏩Anti-CTLA4 responses are the most durable

Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education

🔥off the press Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC JHEP Reports 🔎🗺️RWD study ❓how to best select for TACE > AFP & Tumor burden 🧐helpful for the discussion in the tumor board 👇my author link: doi.org/10.1016/j.jhep… ESMO - Eur. Oncology

The Lancet Oncology: Path response with neoadj immunotherapy associates with RFS in #HCC ⏩Time for randomized neoadj trials in HCC!!! Congratulations David James Pinato 🇺🇦 Antonio D'Alessio for leading this highly collaborative project! doi.org/10.1016/S1470-…

📢Hepatopancreaticobiliary cancers- Oral abstracts #ESMOAsia24 ESMO - Eur. Oncology 1⃣LBA1 - Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04) ✅ ORR:12%, mPFS: 5.4 mo,

Check out our recent review of contemporary & novel IO in HCC! Fantastic effort by VUMC resident and my mentee Shabnam Eghbali, MD. Link below. Dr. Cathy Eng @VUMCMedicineRes @VUMC_Cancer Laura Goff nam12.safelinks.protection.outlook.com/?url=https%3A%…

Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection: brnw.ch/21wQ1TG Authored by james Yu brnw.ch/21wQ1TH #gicsm

🔥off the press Precision surgery for hepatocellular carcinoma The Lancet Gastroenterology & Hepatology doi.org/10.1016/S2468-… 👉the field is moving to precision medicine 👉Our thoughts on current strategies & future opportunities > team work is key for personalized therapy ESMO - Eur. Oncology EASL Education ILCA

Expansive review of IO across solid tumours in collaboration with Dr. Wang and my old colleague and friend Dr. Lei Zheng, now cancer centre director at UT! Clinical development of immuno-oncology therapeutics sciencedirect.com/science/articl…

Original Article Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study Moeckli et al. #LiverX tinyurl.com/yrt77t4k

🟡Is Claudin 18.2 expressed in biliary tract cancers? ESMO Open ✅29.5% express gallbladder: 62.5%, extrahepatic: 53.4%, intrahepatic: 12.9% ✅Positivity (if ≥75% of tumor cells): 5.5% gallbladder: 15.6%, extrahepatic: 8.6%, intrahepatic: 2% ❓A potential target for

#ASCO25 ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm Yelena Y. Janjigian MD ATOMIC #dMMR #CRCsm Frank Sinicrope, MD ➡️Clinical Science Symposium

Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models! Disease site matters! Collaborative effort with Chrystal Paulos and many others Winship Cancer Institute of Emory University Sidney Kimmel Comprehensive Cancer Center Vanderbilt University pubmed.ncbi.nlm.nih.gov/40590857/